{"id":11804,"date":"2023-11-09T23:18:00","date_gmt":"2023-11-09T15:18:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11804"},"modified":"2024-11-07T23:25:14","modified_gmt":"2024-11-07T15:25:14","slug":"eccogene-secures-exclusive-licensing-deal-with-astrazeneca-for-glp-1-agonist-ecc5004","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11804","title":{"rendered":"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004"},"content":{"rendered":"\n<p>Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene&#8217;s GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes, and associated comorbidities.<\/p>\n\n\n\n<p><strong>Financial Terms and Agreement Details<\/strong><br>Eccogene is set to receive an upfront payment of USD 185 million, with the potential to earn up to USD 1.825 billion in future clinical, regulatory, and commercial milestone payments. Additionally, Eccogene will be eligible for net sales-based tiered royalties. This deal is reportedly the largest out-licensing agreement targeting a China-based firm signed this year, according to public data.<\/p>\n\n\n\n<p><strong>ECC5004&#8217;s Clinical Progress and Potential<\/strong><br>ECC5004 is a once-daily, low-dose, oral GLP-1 receptor agonist currently in Phase I clinical trials for healthy subjects and type 2 diabetes patients in the United States. Preliminary results from the Phase I study indicate that ECC5004 may offer differentiated clinical advantages, is well-tolerated, and can promote the reduction of blood sugar and body weight. This acquisition strengthens AstraZeneca&#8217;s existing investigational pipeline in the incretin and non-incretin pathways, which includes a GLP-1\/glucagon agonist (AZD9550) and a long-acting amylin analogue (AZD6234).<\/p>\n\n\n\n<p><strong>About Eccogene<\/strong><br>Eccogene, based in Shanghai, China, was co-founded in 2018 by two former Eli Lilly scientists, CEO Dr. Zhou Jingye, former head of chemistry at Lilly China from 2012, and CSO Dr. Xu Jianfeng. The company&#8217;s focus on innovative drug development has positioned it as a significant player in the global pharmaceutical industry.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,1981,871,86],"class_list":["post-11804","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-eccogene","tag-nasdaq-azn","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene&#039;s GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes, and associated comorbidities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11804\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11804\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-09T15:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-07T15:25:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11804#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11804\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004\",\"datePublished\":\"2023-11-09T15:18:00+00:00\",\"dateModified\":\"2024-11-07T15:25:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11804\"},\"wordCount\":269,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"Eccogene\",\"NASDAQ: AZN\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11804#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11804\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11804\",\"name\":\"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-09T15:18:00+00:00\",\"dateModified\":\"2024-11-07T15:25:14+00:00\",\"description\":\"Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene's GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes, and associated comorbidities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11804#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11804\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11804#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004 - Insight, China&#039;s Pharmaceutical Industry","description":"Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene's GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes, and associated comorbidities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11804","og_locale":"en_US","og_type":"article","og_title":"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11804","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-09T15:18:00+00:00","article_modified_time":"2024-11-07T15:25:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11804#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11804"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004","datePublished":"2023-11-09T15:18:00+00:00","dateModified":"2024-11-07T15:25:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11804"},"wordCount":269,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","Eccogene","NASDAQ: AZN","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11804#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11804","url":"https:\/\/flcube.com\/?p=11804","name":"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-09T15:18:00+00:00","dateModified":"2024-11-07T15:25:14+00:00","description":"Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN). Under the terms of the agreement, AstraZeneca will take over the development and commercialization rights to Eccogene's GLP-1 receptor agonist drug candidate, ECC5004, for the treatment of obesity, type 2 diabetes, and associated comorbidities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11804#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11804"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11804#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11804"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11804\/revisions"}],"predecessor-version":[{"id":11806,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11804\/revisions\/11806"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}